Logo image of CORT

CORCEPT THERAPEUTICS INC (CORT) Stock Fundamental Analysis

NASDAQ:CORT - Nasdaq - US2183521028 - Common Stock - Currency: USD

71.71  -0.08 (-0.11%)

After market: 71.25 -0.46 (-0.64%)

Fundamental Rating

7

Taking everything into account, CORT scores 7 out of 10 in our fundamental rating. CORT was compared to 199 industry peers in the Pharmaceuticals industry. CORT has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CORT is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make CORT a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

CORT had positive earnings in the past year.
In the past year CORT had a positive cash flow from operations.
In the past 5 years CORT has always been profitable.
Each year in the past 5 years CORT had a positive operating cash flow.
CORT Yearly Net Income VS EBIT VS OCF VS FCFCORT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

CORT has a better Return On Assets (16.80%) than 96.98% of its industry peers.
The Return On Equity of CORT (20.78%) is better than 92.96% of its industry peers.
With an excellent Return On Invested Capital value of 16.89%, CORT belongs to the best of the industry, outperforming 92.46% of the companies in the same industry.
CORT had an Average Return On Invested Capital over the past 3 years of 17.94%. This is significantly below the industry average of 41.77%.
Industry RankSector Rank
ROA 16.8%
ROE 20.78%
ROIC 16.89%
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
CORT Yearly ROA, ROE, ROICCORT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

With an excellent Profit Margin value of 20.92%, CORT belongs to the best of the industry, outperforming 93.47% of the companies in the same industry.
CORT's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 20.29%, CORT belongs to the top of the industry, outperforming 85.93% of the companies in the same industry.
CORT's Operating Margin has declined in the last couple of years.
CORT has a Gross Margin of 98.39%. This is amongst the best in the industry. CORT outperforms 97.49% of its industry peers.
CORT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.29%
PM (TTM) 20.92%
GM 98.39%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
CORT Yearly Profit, Operating, Gross MarginsCORT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CORT is creating value.
CORT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CORT has been reduced compared to 5 years ago.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CORT Yearly Shares OutstandingCORT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CORT Yearly Total Debt VS Total AssetsCORT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

CORT has an Altman-Z score of 30.92. This indicates that CORT is financially healthy and has little risk of bankruptcy at the moment.
CORT's Altman-Z score of 30.92 is amongst the best of the industry. CORT outperforms 95.48% of its industry peers.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 30.92
ROIC/WACC1.76
WACC9.58%
CORT Yearly LT Debt VS Equity VS FCFCORT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.35 indicates that CORT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.35, CORT is in line with its industry, outperforming 57.29% of the companies in the same industry.
A Quick Ratio of 3.26 indicates that CORT has no problem at all paying its short term obligations.
CORT has a Quick ratio of 3.26. This is comparable to the rest of the industry: CORT outperforms 59.30% of its industry peers.
Industry RankSector Rank
Current Ratio 3.35
Quick Ratio 3.26
CORT Yearly Current Assets VS Current LiabilitesCORT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

9

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.53% over the past year.
The Earnings Per Share has been growing by 9.71% on average over the past years. This is quite good.
CORT shows a strong growth in Revenue. In the last year, the Revenue has grown by 39.93%.
CORT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.11% yearly.
EPS 1Y (TTM)30.53%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-7.14%
Revenue 1Y (TTM)39.93%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%34.33%

3.2 Future

The Earnings Per Share is expected to grow by 54.37% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 29.15% on average over the next years. This is a very strong growth
EPS Next Y39.43%
EPS Next 2Y65.69%
EPS Next 3Y71.2%
EPS Next 5Y54.37%
Revenue Next Year30.71%
Revenue Next 2Y31.35%
Revenue Next 3Y32.81%
Revenue Next 5Y29.15%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CORT Yearly Revenue VS EstimatesCORT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
CORT Yearly EPS VS EstimatesCORT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 57.83 indicates a quite expensive valuation of CORT.
79.40% of the companies in the same industry are more expensive than CORT, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CORT to the average of the S&P500 Index (28.79), we can say CORT is valued expensively.
Based on the Price/Forward Earnings ratio of 41.48, the valuation of CORT can be described as expensive.
78.39% of the companies in the same industry are more expensive than CORT, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.38. CORT is valued rather expensively when compared to this.
Industry RankSector Rank
PE 57.83
Fwd PE 41.48
CORT Price Earnings VS Forward Price EarningsCORT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CORT is valued a bit cheaper than the industry average as 75.38% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, CORT is valued a bit cheaper than 79.90% of the companies in the same industry.
Industry RankSector Rank
P/FCF 38.62
EV/EBITDA 50.06
CORT Per share dataCORT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
CORT has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CORT's earnings are expected to grow with 71.20% in the coming years.
PEG (NY)1.47
PEG (5Y)5.95
EPS Next 2Y65.69%
EPS Next 3Y71.2%

0

5. Dividend

5.1 Amount

No dividends for CORT!.
Industry RankSector Rank
Dividend Yield N/A

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (4/25/2025, 8:00:00 PM)

After market: 71.25 -0.46 (-0.64%)

71.71

-0.08 (-0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)04-30 2025-04-30/amc
Inst Owners82.09%
Inst Owner Change-34.22%
Ins Owners6.52%
Ins Owner Change0.39%
Market Cap7.57B
Analysts82
Price Target146.12 (103.77%)
Short Float %17.7%
Short Ratio9.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.17%
Min EPS beat(2)-40.2%
Max EPS beat(2)42.54%
EPS beat(4)3
Avg EPS beat(4)12.54%
Min EPS beat(4)-40.2%
Max EPS beat(4)42.54%
EPS beat(8)6
Avg EPS beat(8)14.58%
EPS beat(12)8
Avg EPS beat(12)7.58%
EPS beat(16)11
Avg EPS beat(16)8.96%
Revenue beat(2)1
Avg Revenue beat(2)-3.09%
Min Revenue beat(2)-10.25%
Max Revenue beat(2)4.07%
Revenue beat(4)3
Avg Revenue beat(4)-0.2%
Min Revenue beat(4)-10.25%
Max Revenue beat(4)4.07%
Revenue beat(8)6
Avg Revenue beat(8)0.89%
Revenue beat(12)7
Avg Revenue beat(12)-0.9%
Revenue beat(16)8
Avg Revenue beat(16)-1.83%
PT rev (1m)43.61%
PT rev (3m)91.26%
EPS NQ rev (1m)-5%
EPS NQ rev (3m)-62.75%
EPS NY rev (1m)-11.26%
EPS NY rev (3m)-3.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)11.76%
Valuation
Industry RankSector Rank
PE 57.83
Fwd PE 41.48
P/S 11.21
P/FCF 38.62
P/OCF 38.2
P/B 11.13
P/tB 11.13
EV/EBITDA 50.06
EPS(TTM)1.24
EY1.73%
EPS(NY)1.73
Fwd EY2.41%
FCF(TTM)1.86
FCFY2.59%
OCF(TTM)1.88
OCFY2.62%
SpS6.4
BVpS6.44
TBVpS6.44
PEG (NY)1.47
PEG (5Y)5.95
Profitability
Industry RankSector Rank
ROA 16.8%
ROE 20.78%
ROCE 19.57%
ROIC 16.89%
ROICexc 37.58%
ROICexgc 37.58%
OM 20.29%
PM (TTM) 20.92%
GM 98.39%
FCFM 29.02%
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexcg growth 3Y-18.86%
ROICexcg growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 162.57%
Cap/Sales 0.32%
Interest Coverage 250
Cash Conversion 143.23%
Profit Quality 138.73%
Current Ratio 3.35
Quick Ratio 3.26
Altman-Z 30.92
F-Score6
WACC9.58%
ROIC/WACC1.76
Cap/Depr(3y)72.82%
Cap/Depr(5y)100.78%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)30.53%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-7.14%
EPS Next Y39.43%
EPS Next 2Y65.69%
EPS Next 3Y71.2%
EPS Next 5Y54.37%
Revenue 1Y (TTM)39.93%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%34.33%
Revenue Next Year30.71%
Revenue Next 2Y31.35%
Revenue Next 3Y32.81%
Revenue Next 5Y29.15%
EBIT growth 1Y27.55%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year9.57%
EBIT Next 3Y47.28%
EBIT Next 5Y19.15%
FCF growth 1Y54.37%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y55.91%
OCF growth 3Y5.66%
OCF growth 5Y7.79%